As a Doctor of Pharmacy, Dr. Farrell is uniquely familiar with the challenges of getting off-label use of prescription therapies approved by insurance. As part of her efforts as a member of the Scleroderma Foundation’s Medical and Scientific Advisory Board, she worked to build a case for the use of mycophenolate mofetil (CellCept) in the treatment of systemic sclerosis (scleroderma). Thanks to her efforts, mycophenolate mofetil is now listed in the Medicare drug database for off-label use in scleroderma, paving the way for its inclusion on the drug compendia for other insurance carriers. Dr. Farrell once said, “with rare conditions like systemic sclerosis, every aspect of medical care can be met with a roadblock, especially when it comes to insurance coverage for medication.” Now one less roadblock for this patient population exists. In recognition of her efforts, the Scleroderma Foundation awarded her the 2019 Doctor of the Year. Congratulations to Dr. Farrell! Read more here. Find more information on the Scleroderma Foundation here.